Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Prior Therapies for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04963153
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:56.906597+00:00
Published At
2026-04-13T00:00:00+00:00
Record Updated At
2026-04-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Bladder Urothelial Carcinoma", "Recurrent Renal Pelvis Urothelial Carcinoma", "Recurrent Ureter Urothelial Carcinoma", "Recurrent Urethral Urothelial Carcinoma", "Recurrent Urothelial Carcinoma", "Stage IIIB Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"
protocolSection.identificationModule.nctId
"NCT04963153"
protocolSection.identificationModule.officialTitle
"Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Prior Therapies for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Locally Advanced Bladder Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Renal Pelvis Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Ureter Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Urethral Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Bladder Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Renal Pelvis Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Ureter Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Urethral Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Bladder Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Renal Pelvis Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ureter Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Urethral Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIIB Bladder Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Bladder Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Renal Pelvis Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Ureter Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Urethral Cancer AJCC v8 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.